Moderna Flunks Pivotal CMV Trial, But Read-Through Unlikely

 
• By Alaric DeArment
  
India Uses Advanced Tech, AI In Vaccine Development
Moderna's CMV vaccine, mRNA-1647, failed in a Phase III clinical trial. (Shutterstock)

More from Clinical Trials

More from R&D